Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, ...
November 06 2019 - 7:30AM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a
clinical-stage biopharmaceutical company, today announced that the
Company will host a conference call and live webcast on Wednesday,
November 13, 2019 at 8:00 a.m. ET to discuss operational and
financial results for the quarter ended September 30, 2019, as well
as provide a corporate update.
To participate in the call, please dial (877)
407-5976 (domestic) or (412) 902-0031 (international). The live
webcast will be accessible on the Investors section of Matinas’
website, www.matinasbiopharma.com, and will be archived for 90
days.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage
biopharmaceutical company focused on development of its lead
product candidate, MAT9001, for the treatment of cardiovascular and
metabolic conditions. MAT9001 is a prescription-only omega-3 fatty
acid-based composition, comprised primarily of EPA and DPA, under
development for hypertriglyceridemia, that was specifically
designed to overcome the shortcomings seen from other agents in the
omega-3 class. Company leadership has a deep history and knowledge
of cardiovascular drug development and is supported by a
world-class team of scientific advisors.
In addition, the Company is developing MAT2203,
an oral, encochleated formulation of amphotericin B, to treat
serious invasive fungal infections. The drug is based on Matinas’
proprietary lipid nano-crystal (LNC) platform technology which can
help solve complex challenges relating to the safe and effective
delivery of potent medicines, potentially making them more
targeted, less toxic and orally bioavailable.
Forward Looking Statements
This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to the Company's
anticipated capital and liquidity needs, strategic focus and the
future development of its product candidates, including MAT9001 and
MAT2203, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the anticipated timing of
regulatory interactions, the Company’s ability to identify and
pursue development and partnership opportunities for its products
or platform delivery technology on favorable terms, if at all, and
the ability to obtain required regulatory approval and other
statements that are predictive in nature, that depend upon or refer
to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our
ability to protect the Company's intellectual property; the loss of
any executive officers or key personnel or consultants;
competition; changes in the regulatory landscape or the imposition
of regulations that affect the Company's products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma's
product candidates are all in a development stage and are not
available for sale or use.
Investor Contacts
Peter VozzoWestwicke(443) 213-0505 peter.vozzo@westwicke.com
Ian CooneyDirector – Investor Relations & Corporate
DevelopmentMatinas Biopharma, Inc.(415)
722-4563icooney@matinasbiopharma.com
Source: Matinas BioPharma Holdings, Inc.
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Sep 2023 to Sep 2024